Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Receivables (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Receivables for 16 consecutive years, with $25.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 24.2% to $25.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.5 million, a 24.2% increase, with the full-year FY2024 number at $20.7 million, changed 0.34% from a year prior.
  • Receivables was $25.5 million for Q3 2025 at Xtant Medical Holdings, down from $27.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $27.0 million in Q2 2025 to a low of $6.3 million in Q3 2021.
  • A 5-year average of $15.2 million and a median of $13.7 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: decreased 27.88% in 2021, then soared 94.63% in 2023.
  • Xtant Medical Holdings' Receivables stood at $7.2 million in 2021, then soared by 51.71% to $10.9 million in 2022, then soared by 91.02% to $20.7 million in 2023, then fell by 0.34% to $20.7 million in 2024, then grew by 23.51% to $25.5 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Receivables are $25.5 million (Q3 2025), $27.0 million (Q2 2025), and $23.5 million (Q1 2025).